Page 60 - Read Online

Page 14 of 16 Liu et al. Hepatoma Res 2020;6:7 I http://dx.doi.org/10.20517/2394-5079.2019.39

Hepatol 2017;67:302-9.
5. Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology
2016;64:19-22.
6. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90.
7. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the
absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
8. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a
multidisciplinary team. J Hepatol 2014;60:110-7.
9. Cho EJ, Kwack MS, Jang ES, You SJ, Lee JH, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty
liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011;84:17-22.
10. Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol
Hepatol 2011;26:153-62.
11. Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70:284-93.
12. Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at
the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
13. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:491-4.
14. Sorrentino P, D’Angelo S, Ferbo U, Micheli P, Bracigliano A, et al. Liver iron excess in patients with hepatocellular carcinoma developed
on non-alcoholic steato-hepatitis. J Hepatol 2009;50:351-7.
15. Thillai K, Ross P, Sarker D. Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J
Gastrointest Oncol 2016;8:173-85.
16. Nault JC. The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma. Lancet 2017;389:4-6.
17. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
18. Forner A, Reig M, Bruix J. Hepatocellullar carcinoma. Lancet 2018;391:1301-14.
19. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008;48:858-79.
20. Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: approaching a personalized care. J Hepatol 2015;62:S144-56.
21. Brown ZJ, Heinrich B, Greten TF. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research.
Nat Rev Gastroenterol Hepatol 2018;15:536-54.
22. Lau JKC, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol
2017;241:36-44.
23. Ba Q, Hao M, Huang H, Hou J, Ge A, et al. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin
Cancer Res 2011;17:7625-33.
24. Santos NP, Colaço AA, Oliveira PA. Animal models as a tool in hepatocellular carcinoma research: a review. Tumour Biol 2017;39:1-20.
25. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, et al. Cancer genome landscapes. Science 2013;339:1546-58.
26. Yan J, Caviglia JM, Schwabe RF. Animal models of HCC - when injury meets mutation. J Hepatol 2018;68:193-4.
27. Liu Y, Qi X, Zeng Z, Wang L, Wang J, et al. CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in
adult hepatitis B virus transgenic mice. Sci Rep 2017;7:2796.
28. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular
carcinomas. J Clin Invest 2004;113:1774-83.
29. Katz SF, Lechel A, Obenauf AC, Begus-Nahrmann Y, Kraus JM, et al. Disruption of Trp53 in livers of mice induces formation of
carcinomas with bilineal differentiation. Gastroenterology 2012;142:1229-39.e3.
30. Santoni-Rugiu E, Jensen MR, Thorgeirsson SS. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic
events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res 1998;58:123-34.
31. Kent LN, Bae S, Tsai SY, Tang X, Srivastava A, et al. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular
carcinoma. J Clin Invest 2017;127:830-42.
32. Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, et al. β-catenin activation promotes immune escape and
resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov 2019;9:1124-41.
33. Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol 2013;7:206-23.
34. Dow M, Pyke RM, Tsui BY, Alexandrov LB, Nakagawa H, et al. Integrative genomic analysis of mouse and human hepatocellular
carcinoma. Proc Natl Acad Sci U S A 2018;115:E9879-88.
35. Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis
Rev 1986;5:29-49.
36. He S, Hu B, Li C, Lin P, Tang WG, et al. PDXliver: a database of liver cancer patient derived xenograft mouse models. BMC Cancer
2018;18:550.
37. Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM, et al. Human primary liver cancer-derived organoid cultures
for disease modeling and drug screening. Nat Med 2017;23:1424-35.
38. Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via
orthotopic implantation of histologically intact tissues. Int J Cancer 1996;66:239-43.
39. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Gastroenterology 2006;130:1117-28.
40. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, et al. Application of comparative functional genomics to identify best-fit mouse models